Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Pazopanib and paclitaxel
DRUG
2 trials
Sponsors
University of California, Irvine
, Imperial College London
Conditions
Ovarian Neoplasm
Stage III Melanoma
Stage IV Melanoma
Unresectable Melanoma
Phase 1
[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
Completed
NCT01608009
Imperial College London
Ovarian Neoplasm
Start: 2012-07-31
End: 2016-04-30
Updated: 2017-03-10
Phase 2
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Completed
NCT01107665
University of California, Irvine
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
Start: 2010-08-31
End: 2018-02-28
Updated: 2019-08-07
Related Papers
[<sup>18</sup>F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.
Journal of Clinical Oncology
2019-05-20
1 citations
A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma.
Journal of Clinical Oncology
2014-05-20
3 citations